Evidence map›Paper›PMID 41883174›Full record

ArticleEuropean heart journal. Acute cardiovascular care2026

Cardiac myosin-binding protein C in ST-elevation myocardial infarction.

Ramyah Rajakulasingam, Bashir Alaour, Sam McGrath, Liam S Couch, Yamam Sbeih, Zohya Khalique, Emanuela Falaschetti, Alexander Tindale, Emily-Jane Cantor, Catherine J Beattie and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European heart journal. Acute cardiovascular care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Ramyah RajakulasingamNational Heart and Lung Institute, Imperial College London, Sydney Street, London SW3 6NP,UK.
Bashir AlaourKing's BHF Centre of Research Excellence, King's College London, London, UK.ORCID 0000-0001-5604-1096
Sam McGrathKing's BHF Centre of Research Excellence, King's College London, London, UK.
Liam S CouchKing's BHF Centre of Research Excellence, King's College London, London, UK.
Yamam SbeihKing's BHF Centre of Research Excellence, King's College London, London, UK.
Zohya KhaliqueNational Heart and Lung Institute, Imperial College London, Sydney Street, London SW3 6NP,UK.
Emanuela FalaschettiImperial Clinical Trials Unit, Imperial College London, London, UK.ORCID 0000-0001-6964-2042
Alexander TindaleNational Heart and Lung Institute, Imperial College London, Sydney Street, London SW3 6NP,UK.
Emily-Jane CantorNational Heart and Lung Institute, Imperial College London, Sydney Street, London SW3 6NP,UK.
Catherine J BeattieRoyal Brompton and Harefield Hospitals, Guy's and St Thomas' NHS Foundation Trust, London, UK.
Miles DalbyRoyal Brompton and Harefield Hospitals, Guy's and St Thomas' NHS Foundation Trust, London, UK.
Dudley J PennellNational Heart and Lung Institute, Imperial College London, Sydney Street, London SW3 6NP,UK.
Michael MarberKing's BHF Centre of Research Excellence, King's College London, London, UK.
Ranil de SilvaNational Heart and Lung Institute, Imperial College London, Sydney Street, London SW3 6NP,UK.ORCID 0000-0003-1107-2117

Funding

British Heart Foundation, London
6 · The paper itself

Abstract

aimsCardiac myosin-binding protein C (cMyC) is a novel biomarker of myocardial injury, rising and falling more rapidly than cardiac troponins in myocardial infarction (MI), potentially enabling earlier diagnosis. Its performance has not been assessed in reperfused acute ST-segment elevation myocardial infarction (STEMI), against gold-standard biochemical (high-sensitivity cardiac troponin I, hs-cTnI) or imaging (cardiovascular magnetic resonance, CMR) biomarkers. This study tested the hypotheses that: i) cMyC correlates with acute and final MI size by late gadolinium enhancement (LGE) CMR and ii) cMyC is related to the presence of acute microvascular obstruction (MVO) by CMR. METHODS AND

resultsBlood samples were obtained at 6 ± 2 hourly intervals for 24 hours (hrs) for measurement of hs-cTnI and cMyC concentrations in patients with reperfused acute STEMI. Patients underwent 3T LGE-CMR at ∼3-5 days (n = 69) and ∼4 months (n = 65) after reperfusion. Acute cMyC at all timepoints significantly correlated with acute and final MI size on LGE-CMR, most strongly at 6-hrs post reperfusion (r = 0.7, P < 0.001). cMyC at 6-, 12-, 18- and 24-hrs demonstrated significant discriminatory power in identifying patients with acute MVO, with the 6-hr level having the highest discriminative power. Hs-cTnI correlated more strongly with acute and final MI size compared with cMyC and had significantly higher discriminatory ability in identifying MVO at 12-, 18- and 24-hrs.

conclusioncMyC is a quantitative biochemical biomarker of myocardial injury in reperfused STEMI. Further studies, using optimised high-sensitivity assays, are warranted to evaluate its potential as a novel biomarker after acute MI.

Indexed as

Carrier ProteinsST Elevation Myocardial InfarctionAgedBiomarkersFemaleHumansMagnetic Resonance Imaging, CineMaleMiddle AgedMyosin Binding Protein CTroponin IBiomarkersCarrier ProteinsMyosin Binding Protein CTroponin ICardiac myosin-binding protein CHigh-sensitivity cardiac troponin IMicrovascular obstructionMyocardial infarction sizeMyocardial injuryST-elevation myocardial infarction

Identifiers

PMID41883174
PMCPMC13344176

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.